Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Holding TMDX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.16Last Year’s EPS
0.12Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 07, 2019
|% Change Since: -54.04%
|Next Earnings Date:Jun 11, 2019
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong year-over-year growth in revenue and logistics services, alongside challenges in sequential revenue decline, gross margin pressure, and operational issues related to aircraft maintenance. The commitment to future growth through next-gen technologies is promising, but short-term challenges remain.Company Guidance
During the TransMedics third-quarter 2024 earnings call, the company provided guidance reflecting continued growth despite some challenges. Total revenue for the quarter was $108.8 million, marking a 64% increase from Q3 2023, driven by a 76% growth in U.S. sales, although offset by a 40% decline outside the U.S. (OUS). The company's gross margin for the quarter was 56%, down from 61% in the previous quarter, attributed to increased investments in logistics and next-gen technologies. TransMedics maintained its annual revenue guidance range of $425 million to $445 million, representing 76% to 84% growth over 2023, indicating confidence in a strong finish to the year and several growth catalysts anticipated in 2025.Strong Year-Over-Year Revenue Growth
Total revenue for Q3 2024 was $108.8 million, representing a 64% growth from Q3 2023. U.S. revenue increased by 76% year-over-year.
Significant Growth in Transplant Logistics Revenue
TransMedics transplant logistics service revenue for Q3 was $20.1 million, up from $2.1 million in Q3 2023, marking a substantial increase.
Expansion of Aviation Fleet
TransMedics expanded its fleet to 18 owned aircraft by the end of Q3 2024, supporting future growth in logistics.
Launch of Next-Gen OCS Technologies
Plans to launch next-gen OCS Heart and Lung technologies in 2025, aiming to enhance clinical outcomes and increase transplant volumes.
---
TMDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TMDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 28, 2024 | $126.24 | $88.50 | -29.90% |
| Jul 31, 2024 | $142.26 | $151.51 | +6.50% |
| Apr 30, 2024 | $94.13 | $117.60 | +24.93% |
| Feb 26, 2024 | $77.74 | $88.71 | +14.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TransMedics Group Inc (TMDX) report earnings?
TransMedics Group Inc (TMDX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is TransMedics Group Inc (TMDX) earnings time?
TransMedics Group Inc (TMDX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMDX EPS forecast?
TMDX EPS forecast for the fiscal quarter 2024 (Q4) is 0.16.
---